Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36922| Title: | Anti-CD20 monoclonal antibodies: reviewing a revolution. | Authors: | Opat S. ;Casan J.M.L.;Wong J.;Northcott M.J. | Institution: | (Casan, Wong, Opat) Haematology Department, Monash Health, Melbourne, Australia (Northcott) Rheumatology Department, Monash Health, Melbourne, Australia (Northcott, Opat) School of Clinical Sciences, Monash University, Melbourne, Australia | Issue Date: | 22-Jun-2019 | Copyright year: | 2018 | Publisher: | Taylor and Francis Inc. (325 Chestnut St, Suite 800, Philadelphia PA 19106, United States) | Place of publication: | United States | Publication information: | Human Vaccines and Immunotherapeutics. 14 (12) (pp 2820-2841), 2018. Date of Publication: 02 Dec 2018. | Journal: | Human Vaccines and Immunotherapeutics | Abstract: | Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.Copyright © 2018, © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/21645515.2018.1508624 | PubMed URL: | 30096012 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30096012] | ISSN: | 2164-5515 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/36922 | Type: | Review | Subjects: | cyclophosphamide follicular lymphoma/dt [Drug Therapy] fludarabine Fc receptor/ec [Endogenous Compound] cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine acute lymphoblastic leukemia/dt [Drug Therapy] amino acid sequence ANCA associated vasculitis/dt [Drug Therapy] antigen binding *antineoplastic activity B cell lymphoma/dt [Drug Therapy] Burkitt lymphoma/dt [Drug Therapy] cancer immunization cell killing chronic lymphatic leukemia/dt [Drug Therapy] clinical trial (topic) complement dependent cytotoxicity diffuse large B cell lymphoma/dt [Drug Therapy] down regulation *drug mechanism drug receptor binding event free survival hematologic malignancy/dt [Drug Therapy] human humoral immune deficiency/dt [Drug Therapy] idiopathic thrombocytopenic purpura/dt [Drug Therapy] immune response *immunomodulation *immunosuppressive treatment lack of drug effect leukemia/si [Side Effect] lymphocytic lymphoma/dt [Drug Therapy] lymphoproliferative disease/dt [Drug Therapy] marginal zone lymphoma/dt [Drug Therapy] *molecularly targeted therapy overall survival partial drug response pharmacokinetic parameters progression free survival protein degradation protein expression randomized controlled trial (topic) methotrexate *obinutuzumab/dt [Drug Therapy] ocrelizumab *ofatumumab/dt [Drug Therapy] *rituximab/ae [Adverse Drug Reaction] *rituximab/dt [Drug Therapy] tumor antigen/ec [Endogenous Compound] tumor necrosis factor/ec [Endogenous Compound] veltuzumab *CD20 antibody B lymphocyte receptor/ec [Endogenous Compound] systemic lupus erythematosus/dt [Drug Therapy] smoldering multiple myeloma/dt [Drug Therapy] rheumatoid arthritis/dt [Drug Therapy] review recombinant DNA technology down regulation *drug mechanism drug receptor binding *antineoplastic activity follicular lymphoma / drug therapy hematologic malignancy / drug therapy human humoral immune deficiency / drug therapy idiopathic thrombocytopenic purpura / drug therapy immune response *immunomodulation *immunosuppressive treatment lack of drug effect leukemia / side effect lymphocytic lymphoma / drug therapy lymphoproliferative disease / drug therapy marginal zone lymphoma / drug therapy *molecularly targeted therapy overall survival partial drug response pharmacokinetic parameters progression free survival protein degradation protein expression randomized controlled trial (topic) recombinant DNA technology Review rheumatoid arthritis / drug therapy smoldering multiple myeloma / drug therapy systemic lupus erythematosus / drug therapy event free survival B cell lymphoma / drug therapy Burkitt lymphoma / drug therapy cancer immunization cell killing chronic lymphatic leukemia / drug therapy clinical trial (topic) complement dependent cytotoxicity diffuse large B cell lymphoma / drug therapy acute lymphoblastic leukemia / drug therapy amino acid sequence ANCA associated vasculitis / drug therapy antigen binding |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.